glp-1 prescription guidelines Updated guidance from the PCDS and ABCD: Managing the national RA shortage Nearly Four Million Medicare Beneficiaries

The OpenLoop Health data breach (January 2026) affected ~1.6 million records including MEDVi patients

Losing weight is not something your body wants you to do, its more or less an evolutionary fact that it is very much in support of you retaining excess calories to use as energy later when you are getting chased by a tiger or something

Many users report that they were not warned about the possibility of permanent stomach paralysis or the potential need for feeding tubes or surgeries to manage complications

For patients trying to decide between semaglutide and tirzepatide, the detailed comparison of mechanisms, side effects, and expected outcomes becomes essential reading

Ozempic (Semaglutide) is a new treatment for type 2 diabetes

Diabetes Obes Metab 15(1):1527 Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction